MedTrace Logo

GSK1349572 Mass Balance Study

NCT00828763 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-06-05

No results posted yet for this study

Summary

Mass balance study to determine the recovery of a single radiolabelled dose of GSK1349572 from urine and feces

Conditions

  • Healthy Volunteer

Interventions

DRUG

[14c}-GSK1349572

HIV-Integrase inhibitor labelled with a carbon 14 marker

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00828763 on ClinicalTrials.gov